With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...

As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the ...

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...